Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/30/2003US6670346 Treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans, administering selective estrogen
12/30/2003US6670344 Having greater solubility than native combretastatin A-4, and rapidly regenerate combretastatin A-4 under physiological conditions; for use in cancer therapy
12/30/2003US6670341 Phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone
12/30/2003US6670333 Providing exogenous antiangiogenic protein to endothelial cells associated with said tissue
12/30/2003US6670326 Depsipeptide compound
12/30/2003US6670186 RNA-loaded antigen presenting cells
12/30/2003US6670177 Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus
12/30/2003US6670164 Isolated human kinase proteins
12/30/2003US6669966 Topically applying oxides of bismuth, cobalt, copper, iron, manganese or praseodymium, as ointments or on bandages to improve neovascularization of injuries or skin disorders
12/30/2003US6669958 Gel delivery vehicles for anticellular proliferative agents
12/30/2003US6669951 Using conjugate comprising the compound and a delivery-enhancing transporter wherein the compound is attached to the delivery-enhancing transporter through a linker comprising at least 5 guanidino or amidino moieties
12/30/2003US6669943 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
12/30/2003US6669938 ImmunoConjucates for cancer diagnosis and therapy
12/30/2003US6669935 Transducing endothelial cells of arteries in brain, with genetic vectors including polynucleotides which code for cytolysis drugs; gene therapy; drug delivery
12/30/2003CA2380690C Human osteoclast-derived cathepsin
12/30/2003CA2266015C Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
12/30/2003CA2241923C Receptor-mediated gene transfer system for targeting tumor gene therapy
12/30/2003CA2132976C Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
12/30/2003CA2121358C Thymidine phosphorylase for use in the modulation of cellular proliferation or chemotaxis
12/30/2003CA2080555C Bis(phenyl)ethane derivatives
12/30/2003CA2076063C Sulfated glycosaminoglycanoid derivatives
12/30/2003CA2001765C Chelants possessing ortho ligating functionality and complexes thereof
12/29/2003CA2433983A1 Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses
12/25/2003WO2003106682A1 Hla-a24-restricted cancer antigen peptide
12/25/2003US20030237101 Stem cell factor; modulation of gene expression
12/25/2003US20030236423 Trihydroxy polyunsaturated eicosanoids
12/25/2003US20030236412 Cyclic AMP-specific phosphodiesterase inhibitors
12/25/2003US20030236405 7-hetero-bicyclo[2.2.1]-heptanes
12/25/2003US20030236389 Proteins, polynucleotides encoding them and methods of using the same
12/25/2003US20030236303 Therapeutic compositions and methods of use
12/25/2003US20030236294 Anticancer agents
12/25/2003US20030236291 Antitumor agents
12/25/2003US20030236290 Inhibitors of animal cell motility and growth
12/25/2003US20030236289 Antiinflammatory agents; analgesics; antipyretics; cyclooxygenase inhibitor
12/25/2003US20030236280 Aminotetralin-derived urea modulators of vanilloid VR1 receptor
12/25/2003US20030236276 Phosphodiesterase inhibitor; anticancer agents
12/25/2003US20030236263 Chemical compounds
12/25/2003US20030236258 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
12/25/2003US20030236244 Antiallergens; autoimmune diseases; antiproliferative agents; controlling signal transduction
12/25/2003US20030236230 Comprises 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring; for controlling weight gain in a human or higher mammal
12/25/2003US20030236229 For stimulating the immune system, treating proliferative disorders, or microbial infections
12/25/2003US20030236213 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/25/2003US20030236212 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/25/2003US20030236209 Compositions and methods for the therapy and diagnosis of lung cancer
12/25/2003US20030236193 Methods of treatment using specific binding agents of human angiopoietin-2
12/25/2003US20030236182 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
12/25/2003US20030235908 Adjusting lymphocyte concentration; closed container; discharging filter
12/25/2003US20030235900 Anticancer agents
12/25/2003US20030235869 Biological products
12/25/2003US20030235820 Detecting and identifying tumor related transcripts associated with cancer; screening and monitoring antiproliferative agents
12/25/2003US20030235588 Thioredoxin (TRX); administering histone deacetylase inhibitors such as trichostatin A; for treating inflammation
12/25/2003US20030235585 Methods of treating disorders in which TFN alpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha
12/25/2003US20030235584 Method for preparing anti-MIF antibodies
12/25/2003US20030235582 Anti-IGF-I receptor antibody
12/25/2003US20030235557 Administering two viral vectors containing an immunogenic portion of a wilms' tumor (wt1) polynucleotide operably linked to an expression control sequence
12/25/2003US20030235556 Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
12/25/2003US20030235536 Administering an aerosol, a conjugate of a therapeutic agent and an FcRn binding partner, for treating resipiratory system disorders, drug delivery of an antibody, immunizing vaccines
12/25/2003US20030235534 Methods and compositions for radioimmunotherapy of brain and CNS tumors
12/24/2003WO2003107006A1 Oxaliplatin anti-resistance agent
12/24/2003WO2003107002A1 Chfr protein-catalyzed polyubiquitination of aurora kinase a and aurora kinase b
12/24/2003WO2003106974A2 Diagnosis and treatment of chemoresistant tumors
12/24/2003WO2003106970A2 P27 prevents cellular migration
12/24/2003WO2003106707A1 Method for detecting increased susceptibility to tumours
12/24/2003WO2003106692A2 Methods for the identification of all-antigens and their use for cancer therapy and transplantation
12/24/2003WO2003106669A1 Purified pkb ser 473 kinase and uses thereof
12/24/2003WO2003106659A2 Aptamer-toxin molecules and methods for using same
12/24/2003WO2003106621A2 Anti-igf-i receptor antibody
12/24/2003WO2003106618A2 Novel cancer therapies
12/24/2003WO2003106506A1 Low molecular weight oversulfated polysaccharide
12/24/2003WO2003106505A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
12/24/2003WO2003106504A1 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
12/24/2003WO2003106501A1 Fusion protein comprising angiopoietin receptor-binding and a multimerization domain
12/24/2003WO2003106500A1 Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers
12/24/2003WO2003106498A2 Agonistic binding molecules to the human ox40 receptor
12/24/2003WO2003106469A1 Tumour-inhibiting platinum (ii) oxalate complexes
12/24/2003WO2003106462A1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
12/24/2003WO2003106456A2 New compounds
12/24/2003WO2003106455A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators
12/24/2003WO2003106446A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
12/24/2003WO2003106437A1 2-oxazolidinones and their use as inhibitors of animal cell motility and growth
12/24/2003WO2003106433A1 Deoxyhypusine-synthase inhibitors, pharmaceuticals comprising said inhibitors and uses thereof
12/24/2003WO2003106431A2 Novel hexahydro-pyridazine-3-carbocylic acid hydrazide or hydrazone derivatives, combinatorial libraries containing same, use thereof as medicines, pharmaceutical compositions containing same and methods for preparing same
12/24/2003WO2003106430A1 Benzimidazole inhibitors of poly(adp-ribosyl) polymerase
12/24/2003WO2003106426A1 Compounds, compositions, and methods
12/24/2003WO2003106425A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
12/24/2003WO2003106420A1 2,5-disubstituted 3-mercaptopentanoic acid
12/24/2003WO2003106417A1 Mitotic kinesin inhibitors
12/24/2003WO2003106416A2 Chemical process
12/24/2003WO2003106411A1 24-sulfoximine vitamin d3 compounds
12/24/2003WO2003106410A1 Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
12/24/2003WO2003106401A1 N-bridged selective androgen receptor modulators and methods of use thereof
12/24/2003WO2003106381A2 Human adam-10 inhibitors
12/24/2003WO2003105908A2 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
12/24/2003WO2003105907A2 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
12/24/2003WO2003105895A1 Vaccination with immuno-isolated cells producing an immunomodulator
12/24/2003WO2003105885A1 Novel method of screening
12/24/2003WO2003105880A1 Peptides selectively lethal to malignant and transformed mammalian cells
12/24/2003WO2003105877A1 Pharmaceutical compositions
12/24/2003WO2003105875A1 Immunostimulator having antineoplastic action and method for producing said immunostimulator
12/24/2003WO2003105866A1 Products useful in the treatment of mmr deficient tumours